Relmada Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022
Relmada Therapeutics, Inc. (Nasdaq: RLMD) will report its financial results for Q1 2022 on May 5, 2022, after market close. The company is focused on developing treatments for central nervous system diseases, particularly major depressive disorder (MDD). Notably, its lead program, REL-1017, is in late-stage development and has shown significant antidepressant effects in Phase 2 trials. The company will host a conference call at 4:30 PM ET on the same day to discuss the results and updates.
- REL-1017 demonstrated robust, rapid, and sustained antidepressant effects in Phase 2 trials.
- The Phase 2 study showed favorable pharmacokinetic, safety, and tolerability profiles.
- None.
CORAL GABLES, Fla., April 28, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2022 after the market close on Thursday, May 5, 2022. The company will host a corporate update conference call and live audio webcast at 4:30 PM Eastern Time on Thursday, May 5, 2022.
Live Conference Call & Webcast: | |
Toll Free: | 877-256-3246 |
International: | 212-231-2903 |
Conference ID: | 22017494 |
Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1543079&tp_key=2a9a78ffb7 |
A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment and monotherapy treatment for MDD in adults. In addition, Relmada is advancing a clinical-stage program in neurodegenerative diseases based on psilocybin and select derivative molecules. Learn more at www.relmada.com.
About REL-1017
REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the treatment of MDD. The ongoing RELIANCE Clinical Research Program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment. In a Phase 2 trial, REL-1017 demonstrated robust, rapid, and sustained antidepressant effects with statistically significant improvements compared to placebo. The Phase 2 study also showed a favorable pharmacokinetic, safety, and tolerability profile of REL-1017 consistent with results observed in previously completed Phase 1 studies.
Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.
Investor Contact:
Tim McCarthy
LifeSci Advisors
212-915-2564
Tim@LifeSciAdvisors.com
Media Inquiries:
FischTank PR
Relmada@FischTankPR.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/relmada-therapeutics-to-report-first-quarter-2022-financial-results-and-host-conference-call-and-webcast-on-may-5-2022-301535398.html
SOURCE Relmada Therapeutics, Inc.
FAQ
When will Relmada Therapeutics report its Q1 2022 financial results?
What is the focus of Relmada Therapeutics?
What are the results of the REL-1017 Phase 2 trials?
What time is the Relmada Therapeutics conference call on May 5, 2022?
